Etanidazole

08/01/1984 - "The purpose of the present study was to test various ways of depleting GSH levels in a variety of experimental mouse tumors, to measure the improvement in the efficacy of MISO and its less toxic analog SR 2508 by this depletion, and to determine the effect of daily GSH depletion on the toxicity of MISO and SR 2508. "
05/01/1989 - "BSO pretreatment increased the efficacy of SR 2508 with single dose radiation in the MCA but not RIF tumor. "
08/01/1984 - "The efficacy of MISO and SR 2508 was evaluated using the KHT and SCC VII tumors either by the regrowth delay assay or by the in vivo/in vitro clonogenic assay. "
08/01/2014 - "The aims of this study were to evaluate the cell survival uncertainty distribution of radiation and to assess the accuracy of predictions of tumor response by using three different in vitro experimental cell cultures with radiosensitizers (including etanidazole). "
12/01/2004 - "The present studies were undertaken to determine whether 19F MRS could be used to quantify the binding of the pentafluorinated derivative of etanidazole (EF5) in hypoxic cells of solid tumors. "

04/01/1991 - "The combination of hyperthermia and etanidazole increased the killing of both dim and bright cells exposed to radiation by approximately 10-fold versus 10 Gy alone."
07/01/1995 - "The impact of etanidazole on the therapeutic index of hyperthermia, radiation therapy and cisplatin may be worth of study, especially since a positive interaction between these modalities is found in laboratory models."
07/01/1995 - "Treatment was given once weekly and consisted of etanidazole 3 gm/m2 IV bolus, cisplatin 50 mg/m2 IV bolus, hyperthermia for 60 min with a target temperature of 43 degrees C, and radiation therapy 500 cGy/fraction (median total dose 3000 cGy) for a total of six weeks. "
11/01/1992 - "The combination of etanidazole (1 g/kg) and the platinum complexes followed by whole-body hyperthermia produced marked increases in tumour growth delay ranging from 2.5- to 3.6-fold over the growth delays obtained with the platinum complexes alone. "
07/01/1995 - "Five patients (six hyperthermia sites) with advanced superficial tumours were treated with combined etanidazole, cisplatin, local hyperthermia, and radiation therapy as part of a Phase I pilot study. "

04/01/1991 - "Etanidazole and radiation therapy cause rapid regression, but not cure, of feline squamous cell carcinoma. "
04/01/1991 - "Eleven cats with feline squamous cell carcinoma were treated with intratumoral Etanidazole and radiation therapy. "
01/01/1991 - "The objectives of the study were to determine the toxicity and efficacy of SR 2508, combined with conventional radiotherapy for the management of unresectable stage III and IV head and neck squamous carcinomas. "
04/01/1991 - "Technique, pharmacokinetics, toxicity, and efficacy of intratumoral etanidazole and radiotherapy for treatment of spontaneous feline oral squamous cell carcinoma."
09/01/1997 - "The aim of the study was to evaluate the efficacy and toxicity of Etanidazole, a hypoxic cell sensitizer, combined with radiotherapy in the treatment of head and neck squamous cell carcinoma. "

06/15/1995 - "The results showed that adding Etanidazole to conventional RT produced no global benefit for patients who had advanced head and neck carcinomas. "
01/01/1992 - "Thirty-four patients affected by primary pulmonary carcinoma or in a state of recurrence after surgery were analyzed and 2g/m2 of etanidazole was administered intravenously. "
01/01/1992 - "Kinetic uptake of etanidazole in lung carcinoma and normal tissue in vivo."
03/01/1989 - "Experimental intra-arterial administration of SR-2508 in the rabbit V2 carcinoma model."
09/01/1997 - "Results of a European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas."

01/01/1992 - "Fifty-four patients have been entered on a Phase II trial to study the efficacy of etanidazole (ETA) for locally advanced prostate cancer. "
01/01/1992 - "The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer."
11/01/1995 - "RTOG's first quality of life study--RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer."
10/01/1996 - "Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20)."
06/15/1994 - "Phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer."